Analyst Price Target is $5.00
▲ +623.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for DBV Technologies in the last 3 months. The average price target is $5.00, with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 623.59% upside from the last price of $0.69.
Current Consensus is
Hold
The current consensus among 3 investment analysts is to hold stock in DBV Technologies. This Hold consensus rating has held steady for over two years.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More
